Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2

被引：196

作者：

McDonald, Ian ^{[1
]}

Murray, Sam M. ^{[1
]}

Reynolds, Catherine J. ^{[1
]}

Altmann, Daniel M. ^{[2
]}

Boyton, Rosemary J. ^{[1
,3
]}

机构：

[1] Imperial Coll London, Fac Med, Dept Infect Dis, London, England

[2] Imperial Coll London, Fac Med, Dept Immunol & Inflammat, London, England

[3] Royal Brompton & Harefield Hosp, Lung Div, London, England

来源：

NPJ VACCINES | 2021年 / 6卷 / 01期

基金：

英国医学研究理事会;

关键词：

NEUTRALIZING ANTIBODY; HEALTHY-ADULTS; PROTECTIVE EFFICACY; IMMUNE-RESPONSES; SARS; CORONAVIRUS; COVID-19; SAFETY; ADENOVIRUS; MONKEYS;

D O I：

10.1038/s41541-021-00336-1

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

As SARS-CoV-2 vaccines are deployed worldwide, a comparative evaluation is important to underpin decision-making. We here report a systematic literature review and meta-analysis of Phase I/II/III human trials and non-human primates (NHP) studies, comparing reactogenicity, immunogenicity and efficacy across different vaccine platforms for comparative evaluation (updated to March 22, 2021). Twenty-three NHP and 32 human studies are included. Vaccines result in mostly mild, self-limiting adverse events. Highest spike neutralizing antibody (nAb) responses are identified for the mRNA-1273-SARS-CoV and adjuvanted NVX-CoV2373-SARS-CoV-2 vaccines. ChAdOx-SARS-CoV-2 produces the highest T cell ELISpot responses. Pre-existing nAb against vaccine viral vector are identified following AdH-5-SARS-CoV-2 vaccination, halving immunogenicity. The mRNA vaccines depend on boosting to achieve optimal immunogenicity especially in the elderly. BNT162b2, and mRNA-1273 achieve >94%, rAd26/5 > 91% and ChAdOx-SARS-CoV-2 > 66.7% efficacy. Across different vaccine platforms there are trade-offs between antibody binding, functional nAb titers, T cell frequency, reactogenicity and efficacy. Emergence of variants makes rapid mass rollout of high efficacy vaccines essential to reduce any selective advantage.

引用

页数：14

共 86 条

[1] Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas [J].

Adney, Danielle R. ;

Wang, Lingshu ;

van Doremalen, Neeltje ;

Shi, Wei ;

Zhang, Yi ;

Kong, Wing-Pui ;

Miller, Megan R. ;

Bushmaker, Trenton ;

Scott, Dana ;

de Wit, Emmie ;

Modjarrad, Kayvon ;

Petrovsky, Nikolai ;

Graham, Barney S. ;

Bowen, Richard A. ;

Munster, Vincent J. .

VIRUSES-BASEL, 2019, 11 (03)

[2] What policy makers need to know about COVID-19 protective immunity [J].

Altmann, Daniel M. ;

Douek, Daniel C. ;

Boyton, Rosemary J. .

LANCET, 2020, 395 (10236) :1527-1529

[3] Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults [J].

Anderson, E. J. ;

Rouphael, N. G. ;

Widge, A. T. ;

Jackson, L. A. ;

Roberts, P. C. ;

Makhene, M. ;

Chappell, J. D. ;

Denison, M. R. ;

Stevens, L. J. ;

Pruijssers, A. J. ;

McDermott, A. B. ;

Flach, B. ;

Lin, B. C. ;

Doria-Rose, N. A. ;

O'Dell, S. ;

Schmidt, S. D. ;

Corbett, K. S. ;

Swanson, P. A., II ;

Padilla, M. ;

Neuzil, K. M. ;

Bennett, H. ;

Leav, B. ;

Makowski, M. ;

Albert, J. ;

Cross, K. ;

Edara, V. V. ;

Floyd, K. ;

Suthar, M. S. ;

Martinez, D. R. ;

Baric, R. ;

Buchanan, W. ;

Luke, C. J. ;

Phadke, V. K. ;

Rostad, C. A. ;

Ledgerwood, J. E. ;

Graham, B. S. ;

Beigel, J. H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) :2427-2438

[4] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J].

Baden, Lindsey R. ;

El Sahly, Hana M. ;

Essink, Brandon ;

Kotloff, Karen ;

Frey, Sharon ;

Novak, Rick ;

Diemert, David ;

Spector, Stephen A. ;

Rouphael, Nadine ;

Creech, C. Buddy ;

McGettigan, John ;

Khetan, Shishir ;

Segall, Nathan ;

Solis, Joel ;

Brosz, Adam ;

Fierro, Carlos ;

Schwartz, Howard ;

Neuzil, Kathleen ;

Corey, Larry ;

Gilbert, Peter ;

Janes, Holly ;

Follmann, Dean ;

Marovich, Mary ;

Mascola, John ;

Polakowski, Laura ;

Ledgerwood, Julie ;

Graham, Barney S. ;

Bennett, Hamilton ;

Pajon, Rolando ;

Knightly, Conor ;

Leav, Brett ;

Deng, Weiping ;

Zhou, Honghong ;

Han, Shu ;

Ivarsson, Melanie ;

Miller, Jacqueline ;

Zaks, Tal .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :403-416

[5]

Bao L, 2020, BIORXIV, DOI [DOI 10.1101/2020.03.13.990226V2, DOI 10.1101/2020.03.13.990226]

[6] Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS [J].

Bukreyev, A ;

Lamirande, EW ;

Buchholz, UJ ;

Vogel, LN ;

Elkins, WR ;

St Claire, M ;

Murphy, BR ;

Subbarao, K ;

Collins, PL .

LANCET, 2004, 363 (9427) :2122-2127

[7]

Castells MC, 2021, NEW ENGL J MED, V384, P643, DOI [10.1056/NEJMra2035343, 10.1056/NEJMc2100766]

[8] Randomized, Double-Blinded, Placebo-Controlled Phase 2 Trial of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in Healthy Adults [J].

Che, Yanchun ;

Liu, Xiaoqiang ;

Pu, Yi ;

Zhou, Meijian ;

Zhao, Zhimei ;

Jiang, Ruiju ;

Yin, Zhifang ;

Xu, Mingjue ;

Yin, Qiongzhou ;

Wang, Jianfeng ;

Pu, Jing ;

Zhao, Heng ;

Zhang, Ying ;

Wang, Lichun ;

Jiang, Ya ;

Lei, Jin ;

Zheng, Yan ;

Liao, Yun ;

Long, Runxiang ;

Yu, Li ;

Cui, Pingfang ;

Yang, Huijuan ;

Zhang, Yuehui ;

Li, Jingyu ;

Chen, Weiwu ;

He, Zhanlong ;

Ma, Kaili ;

Hong, Chao ;

Li, Dandan ;

Jiang, Guorun ;

Liu, Donglan ;

Xu, Xingli ;

Fan, Shengtao ;

Cheng, Chen ;

Zhao, Hongling ;

Yang, Jianbo ;

Li, Yan ;

Zou, Yanxiang ;

Zhu, Youshuai ;

Zhou, Yaling ;

Guo, Yingqiu ;

Yang, Ting ;

Chen, Hongbo ;

Xie, Zhongping ;

Li, Changgui ;

Li, Qihan .

CLINICAL INFECTIOUS DISEASES, 2021, 73 (11) :E3949-E3955

[9] The SARS-CoV-2 Vaccine Pipeline: an Overview [J].

Chen, Wen-Hsiang ;

Strych, Ulrich ;

Hotez, Peter J. ;

Bottazzi, Maria Elena .

CURRENT TROPICAL MEDICINE REPORTS, 2020, 7 (02) :61-64

[10] Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region [J].

Chen, ZW ;

Zhang, LQ ;

Qin, CA ;

Ba, L ;

Yi, CE ;

Zhang, FW ;

Wei, Q ;

He, T ;

Yu, WJ ;

Yu, J ;

Gao, H ;

Tu, XM ;

Gettie, A ;

Farzan, M ;

Yuen, KY ;

Ho, DD .

JOURNAL OF VIROLOGY, 2005, 79 (05) :2678-2688

← 1 2 3 4 5 6 7 8 9 →